

## Contents lists available at ScienceDirect

## Heliyon

journal homepage: www.cell.com/heliyon



## Corrigendum



Corrigendum to "Going for a stroll on lurasidone: Considerations on an atypical case of acute compartment syndrome of both legs" [Heliyon 9(4) (April 2023) e15047]\*

L. Bosco <sup>a,g</sup>, T. Russo <sup>a</sup>, Y.M. Falzone <sup>a</sup>, C. Butera <sup>b</sup>, A. Del Prete <sup>e</sup>, R. Mellone <sup>e</sup>, U. Del Carro <sup>b</sup>, M. Filippi <sup>a,b,c,d,f</sup>, S.C. Previtali <sup>a,g,\*</sup>

- <sup>a</sup> Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
- <sup>b</sup> Neurophysiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
- <sup>c</sup> Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
- d Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy
- <sup>e</sup> Department of Radiology and Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy
- f Vita-Salute San Raffaele University, Milan, Italy
- g Neuromuscular Repair Unit, INSPE and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy

Line 48-53.

A 34-year-old woman with a history of severe obesity and psychotic depression in therapy with lurasidone (92.5mg/day) for four months, and chronic therapy with low dosages of promazine (14mg/day) presented to our emergency department for a three-day history of bilateral foot-drop and painful swelling of the legs. The evening prior to symptom onset, the patient reported a five-kilometer flat walk, which was rather unusual for her otherwise sedentary routine and unprecedented since the time she began lurasidone therapy.

Line 125-128.

After careful consideration, we believe that the patient's prior long-term exposure to promazine, along with the very low-dosages and its shorter half-life, make it improbable that promazine had a substantial concomitant impact on the event (Adverse Drug Reaction Probability Scale = -1), although a drug interaction effect with lurasidone cannot be excluded.

Line 148.

We thank Dr. Federico Montini for helpful suggestion.

The authors/publisher apologize for the errors. Both the HTML and PDF versions of the article have been updated to correct the errors.

## Declaration of competing interest

The authors declare no conflict of interest.

https://doi.org/10.1016/j.heliyon.2023.e16549

DOI of original article: https://doi.org/10.1016/j.heliyon.2023.e15047.

<sup>\*</sup> In the original published version of this article, the authors missed to add the patient's medical history which doesn't affect the conclusion and confirmed the corrected statement with the editor of the paper (line 48–53, line 125–128 and line 148). The correct version can be found below.

<sup>\*</sup> Corresponding author. Neuromuscular Repair Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy. E-mail address: previtali.stefano@hsr.it (S.C. Previtali).